China Healthcare Weekly (Jun.1)-Akeso/Summit's Disappointing Ph3 Readout,Valuation Outlook of Biokin

412 Views02 Jun 2025 09:16

CR Sanjiu plans to transfer 49.8967% equity of Sanjiu (Anguo).Summit/Akeso's disappointing phase 3 readout raises doubts on FDA approval for AK112.Biokin is overvalued compared to Akeso and Kelun Bio

What is covered in the Full Insight:

Introduction
China Resources and Strategic Moves
Clinical Trials and FDA Approvals
Market Analysis and Valuation Outlook
Risks and Final Thoughts

Xinyao (Criss) Wang

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 4-minute read)

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream